Search Results

You are looking at 31 - 40 of 55 items for :

  • "hepatitis B virus" x
  • Refine by Access: All x
Clear All
Full access

Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt, and Benjamin R. Tan

an additional 33.3% patients were overweight (BMI, 25–30 kg/m 2 ). Less than 35% had a diagnosis of cirrhosis based on pathology and imaging review. A total of 21 patients were hepatitis C virus (HCV)–positive and 9 were hepatitis B virus (HBV

Full access

Ali A. Mokdad, Amit G. Singal, Jorge A. Marrero, Hao Zhu, and Adam C. Yopp

treatment of the intrahepatic tumor burden combined with systemic therapy may be more efficacious. This more aggressive approach has been advocated by the Hong Kong Liver Cancer (HKLC) staging system in patients primarily with hepatitis B virus (HBV

Full access

Amit G. Singal, Akbar K. Waljee, Nishant Patel, Emerson Y. Chen, Jasmin A. Tiro, Jorge A. Marrero, and Adam C. Yopp

). Patients were classified according to origin of liver disease, including hepatitis C virus (HCV), hepatitis B virus, alcohol-related liver disease, and nonalcoholic fatty liver disease (NAFLD). Laboratory data of interest at time of diagnosis and treatment

Full access

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom, and Nadeem Zafar

factor (e.g., blood transfusion, intravenous drug abuse) or from a region with a nonnegligible prevalence of hepatitis B infection. Further discussion is provided in Hepatitis B Virus Reactivation on the facing page. Hepatitis C testing is needed in high

Full access

Ali Mokdad, Travis Browning, John C. Mansour, Hao Zhu, Amit G. Singal, and Adam C. Yopp

patient's medical record was performed to obtain patient demographics, clinical history, laboratory data, and imaging results. Clinical history of interest included hepatitis C virus (HCV) and hepatitis B virus (HBV) serostatus, alcohol abuse (defined as

Full access

Hanna K. Sanoff, YunKyung Chang, Joseph M. Stavas, Til Stürmer, and Jennifer Lund

codes for hepatitis B virus, hepatitis C virus, alcoholic cirrhosis, and other cirrhosis. Noncirrhotic comorbidity was determined using the Klabunde modification of the Charlson comorbidity index (CCI). 28 All claims-based covariates were ascertained in

Full access

Ashwin Rao, Nicole E. Rich, Jorge A. Marrero, Adam C. Yopp, and Amit G. Singal

alcohol history, lifetime smoking history, and ECOG performance status. Data regarding liver disease included liver disease etiology (hepatitis C virus [HCV], hepatitis B virus [HBV], alcohol-related liver disease, and nonalcoholic fatty liver disease) 27

Full access

Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen, and Barbara A. Olson-Bullis

.63.0830 26644527 43. Hsu PI , Lai KH , Cheng JS , . Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area . Hepatology 2015 ; 62 : 387 – 396 . 10.1002/hep.27843

Full access

Amit G. Singal, Jorge A. Marrero, and Adam Yopp

and the presence of decompensation (ascites or encephalopathy). Patients were classified according to the cause of liver disease, including HCV, hepatitis B virus, alcohol-related liver disease, NAFLD, and other. Laboratory data of interest included

Full access

Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A. M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar

. 81 , 82 In particular, tuberculosis, progressive multifocal leukoencephalopathy, reactivation of hepatitis B virus, and herpes simplex virus have been reported in patients treated with ruxolitinib. 83 – 87 Patients should be monitored for signs and